🇺🇸 FDA
Patent

US 10640493

Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer

granted A61PA61P35/00

Quick answer

US patent 10640493 (Phthalazine derivatives as inhibitors of PARP1, PARP2, and/or tubulin useful for the treatment of cancer) held by The Regents of the University of California expires Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue May 05 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61P, A61P35/00